Most people first hear about Tesamorelin through a hormone optimization clinic or a late-night deep dive into peptide forums.

Either way, the same questions come up: what does it actually do, how do you dose it, and is the evidence real?

This guide covers the mechanism, the protocol, realistic results, and what to watch out for.

What Tesamorelin Is

Tesamorelin is a synthetic peptide made up of 44 amino acids, classified as a growth hormone-releasing hormone (GHRH) analogue.

The Canadian biotech company Theratechnologies developed it, and the FDA approved it in 2010 under the brand name Egrifta for reducing excess visceral adipose tissue in HIV-positive adults with lipodystrophy.

That approval matters because tesamorelin is one of the only peptides in the GH secretagogue space that completed full Phase III clinical trials with regulatory backing.

Most peptides people compare it to, like Ipamorelin, CJC-1295, and Sermorelin, don’t carry that level of clinical validation.

Since approval, tesamorelin peptide therapy has gained traction in anti-aging medicine and body composition clinics, including practices like Bowery Clinic that integrate peptides into broader hormone optimization protocols.

How the Mechanism Works

Unlike direct human growth hormone (HGH) injections, tesamorelin doesn’t put a flat dose of growth hormone into your bloodstream.

It binds to GHRH receptors on the anterior pituitary gland and signals it to produce and release GH on its own.

The result is a pulsatile release pattern, where GH spikes, does its job, and clears.

This closely mirrors what happens during deep slow-wave sleep or after heavy compound resistance training.

Because the pituitary stays in control, your body’s natural feedback loop remains intact.

That built-in regulation is why tesamorelin tends to carry a lower risk of insulin resistance and fluid retention compared to exogenous HGH administration.

Once growth hormone is circulating, the liver converts a portion into insulin-like growth factor 1 (IGF-1), the downstream molecule responsible for fat metabolism, tissue repair, and collagen synthesis.

Why Visceral Fat Is the Primary Target

Tesamorelin’s main clinical benefit is visceral fat reduction, the deep abdominal fat that wraps around internal organs like the liver and pancreas.

This isn’t the pinchable layer under your skin.

Visceral adipose tissue is metabolically active, and excess amounts are linked to cardiovascular disease, type 2 diabetes, and chronic systemic inflammation.

Growth hormone-driven lipolysis breaks down stored triglycerides and hits visceral stores preferentially.

The Phase III trials behind Egrifta’s FDA approval showed an average 18% reduction in trunk fat over 26 weeks.

Subcutaneous fat in other areas didn’t change nearly as dramatically, which confirms the mechanism is selective rather than systemic.

Daily Protocol: Dosing, Timing, and Injection

The standard tesamorelin dosage is 2 mg injected subcutaneously once per day, typically in the abdominal area.

Timing has a real impact on effectiveness.

Most users inject either first thing in the morning or before bed, always on an empty stomach.

Carbohydrates and insulin spikes blunt the GH response, so eating within 30 minutes of injection reduces the peptide’s benefit.

Reconstitute the lyophilized powder with bacteriostatic water by gently swirling the vial.

Never shake it, because aggressive agitation degrades the peptide chains.

Use a 29- to 31-gauge insulin syringe, pinch a fold of skin at the injection site, insert at a 45-degree angle, and inject slowly.

Rotate injection sites between the left and right sides of the abdomen to prevent localized tissue changes.

After reconstitution, store the vial refrigerated at 2 to 8°C and use within 14 days.

Prescribing clinicians typically run protocols for 12 to 26 weeks as an initial course, with some using a cycling approach of 12 weeks on and 4 weeks off to preserve pituitary receptor sensitivity.

Realistic Results and Timeline

Weeks 1 to 4: IGF-1 levels begin rising in bloodwork, though visible body composition changes haven’t arrived yet.

Improvements in sleep depth and exercise recovery often show up during this early window.

Weeks 4 to 8: Subtle changes in abdominal firmness start appearing.

Clothes may fit differently around the midsection before the mirror shows anything obvious.

Skin quality and energy levels often improve as collagen synthesis increases.

Weeks 8 to 16: This is where measurable fat loss becomes apparent.

Waist circumference drops, and DEXA scans or abdominal CT imaging show clear reductions in visceral fat.

Weeks 16 to 26: Continued reduction with diminishing incremental gains, as most visceral fat loss front-loads in the first 16 weeks.

One honest caveat: tesamorelin won’t compensate for a caloric surplus or a sedentary routine.

The best outcomes consistently come from individuals who pair the peptide with structured resistance training and controlled nutrition.

Side Effects and Safety

The most common side effects are mild and typically resolve quickly.

Injection site reactions like redness or itching fade within minutes.

Joint stiffness is a direct consequence of elevated GH and tends to be dose-dependent.

Mild water retention in the hands and feet is most noticeable during the first two weeks.

The more important concern involves blood glucose.

Growth hormone reduces insulin sensitivity, so individuals with prediabetes or type 2 diabetes need careful monitoring.

Fasting glucose, fasting insulin, and HbA1c should all be tracked before and during treatment.

Tesamorelin is contraindicated during pregnancy and should not be used by anyone with an active malignancy or a history of pituitary pathology.

Bloodwork: What to Track

Running tesamorelin without monitoring labs is like training without tracking progress.

Before starting, get baseline readings for IGF-1, fasting glucose, fasting insulin, HbA1c, a comprehensive metabolic panel, and a full lipid panel.

Repeat the same panel at 8 to 12 weeks to confirm IGF-1 has risen into the target range and that metabolic markers remain stable.

Ongoing monitoring every 3 to 4 months keeps the protocol dialed in and catches any drift before it becomes a problem.

Who This Is Actually For

Tesamorelin fits a specific profile: adults typically over 35 who are already training consistently, eating well, sleeping enough, and managing stress.

These are people who’ve hit a wall where visceral fat persists despite doing everything right, and age-related GH decline is likely contributing.

It remains the standard of care for HIV-associated lipodystrophy, where trunk fat accumulation is a recognized complication of antiretroviral therapy.

If your primary goal is muscle gain rather than fat reduction, other peptide combinations may be better aligned, though the improved recovery and sleep quality tesamorelin provides certainly supports training adaptation.

Putting It Together

Tesamorelin works, and the data behind it is stronger than most options in the peptide space.

But it delivers best when treated as one piece of a broader protocol: progressive training, solid nutrition, protected sleep, and consistent lab monitoring.

Find a prescribing clinician who understands peptide therapy beyond writing the script.

What you build with this tool is still up to you.

This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before beginning any peptide therapy protocol.

Stay updated, free articles. Join our Telegram channel

Join